The U.S. Food and Drug Administration approved a priority supplemental New Drug Application (sNDA) for the combination of Jazz Pharmaceuticals' Zepzelca (lurbinectedin) with Roche's Tecentriq (atezolizumab) or Tecentriq Hybreza as maintenance therapy in adults with extensive-stage small-cell lung cancer (SCLC) who have not progressed following first-line induction therapy. The approval, based on the phase III Imforte study, demonstrated a 46% reduction in risk of disease progression or death and a 27% reduction in risk of death compared to atezolizumab alone. This represents the first combination therapy cleared for first-line maintenance in this indication.